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Abstract 
A chronic inflammatory condition may underlie neurodegenerative disorders, including 
Parkinson’s disease (PD) and Alzheimer’s disease (AD). For example, both PD and AD 
patients show an increase in transforming growth factor-β1 (TGF-β1) levels in their 
cerebrospinal fluid (CSF). TGF-β1 is a cytokine that inhibits inflammation. In the present study, 
using an enzyme-linked immunosorbent assay, we tested the hypothesis that the level of TGF-
β1 in the CSF of patients with amyotrophic lateral sclerosis (ALS), spinocerebellar 
degeneration (SCD), or multiple system atrophy-cerebellar subtype (MSA-C) would be 
elevated compared with that of normal controls. We found that TGF-β1 levels in the CSF were 
not significantly different between these patients and normal controls. Our data suggest that 
the level of TGF-β1 in the CSF is an unreliable biomarker of ALS, SCD, and MSA-C. 
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1. Introduction 
 
Neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and 
spinocerebellar degeneration (SCD), are rare, adult-onset, fatal, progressive motor 
dysfunctions of mostly uncertain etiology. ALS is characterized by the selective and rapid 
degeneration of motor neurons [1]. SCD involves a variable degree of degeneration, mainly in 
the cerebellum, and is hereditary in some cases. Multiple system atrophy (MSA) presents 
clinically with progressive autonomic failure and parkinsonian, cerebellar, and pyramidal 
features in various combinations [2]. MSA is classified into a parkinsonian variant (MSA-P) 
associated with striatonigral degeneration and a cerebellar subtype (MSA-C) with 
olivopontocerebellar atrophy, if cerebellar features dominate. It is often difficult to make a 
differential diagnosis between SCD and MSA-C because both diseases exhibit predominant 
cerebellar symptoms [3]. Conquering these neurodegenerative diseases will require not only 
clarifying the pathophysiology of these diseases and determining therapeutic intervention but 
also identifying clinical biomarkers for diagnosis in the early stage of the diseases. Currently, 
however, there is no available and approved effective biomarker for the early-stage diagnosis 
of these diseases.  
The extracellular space in the brain contains cerebrospinal fluid (CSF). Changes in the 
molecular constituents of the CSF are suggestive of neurological disease-related changes in the 
central nervous system [4]. Transforming growth factor-β (TGF-β) proteins are secreted into 
the CSF. TGF-βs are multifunctional cytokines that regulate the development and repair of 
many cell types, including the proliferation, cell death, and differentiation of neuronal cells [5]. 
In mammals, there are three different isoforms of TGF-βs: TGF-β1, TGF-β2, and TGF-β3. 
TGF-β1 is a 25-kD multifunctional polypeptide that mediates various cellular functions, such 
as the anti-inflammatory response, differentiation of glial cells and immune cells, and tissue 
repair [6–8].  
Mounting evidence suggests that neurodegenerative diseases are a chronic inflammatory 
condition. For example, an elevated TGF-β1 level was found in the lumbar CSF of Alzheimer’s 
disease patients [9]. Elevated TGF-β1 levels have also been reported in the ventricular CSF of 
patients with Parkinson’s disease [10]. These findings suggest that elevated TGF-β1 levels in 
the CSF may be a biomarker for other neurodegenerative diseases, such as SCD and MSA-C. 
However, no study has compared the CSF-TGF-β1 levels between such patients and normal 
controls.  
In the present study, we hypothesized that the TGF-β1 concentration in the CSF of patients 
with SCD or MSA-C was higher than that of normal controls. To prove this hypothesis, we 
performed a pilot study to measure the TGF-β1 levels in the CSF using an enzyme-linked 
immunosorbent assay. 
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2. Materials and Methods 
 
2.1. Patient samples 
 
After obtaining the local ethics committee’s approval and informed consent, CSF samples 
were obtained from both male and female Japanese subjects (Table 1; n = 75), which included 
normal individuals without a neurological disease as controls (n = 19, M/F; 8/11) and patients 
with ALS (n = 27, 17/10), SCD (n = 13, 9/4), and MSA-C (n = 16, 9/7). ALS and MSA-C was 
diagnosed according to the El Escorial Diagnostic Criteria [11] or Second consensus statement 
on the diagnosis of multiple system atrophy revised by Gilman et al. [3, 12], respectively. All 
SCD indicating the pure cerebellum symptom made gene analyses and were diagnosed as 
SCA6 (n = 4), SCA31 (n = 3), SCA3 (n = 1), DRPLA (n = 1) or Holms type cerebellar ataxia 
(n = 4). The CSF samples were obtained using a lumbar puncture from patients after clinical 
suspicion of a neurological disease. Next, the CSF samples were centrifuged at 2,000 rpm for 
20 min to sediment other insoluble material and cells. The supernatant was then frozen and 
stored at –80oC until assayed.  
 
2.2. Enzyme-linked immunosorbent assay (ELISA) analyses 
 
To measure TGF-β1 concentrations in CSF samples, we first neutralized 20 μL of each of 
the acidified CSF samples by adding 20 μL of 1.2 N NaOH/0.5 M HEPES. After neutralization, 
the TGF-β1 concentrations were measured using a Quantikine ELISA Kit (SB100B; R&D 
Systems, Inc., MN, USA). The absorbance was measured at 450 nm (reference 570 nm) using 
a plate reader (Model 680; Bio-Rad Laboratories, Inc., CA, USA). We then compared the TGF-
β1 levels in the CSF of normal subjects with those of ALS, SCD, and MSA-C patients.  
 
2.3 Statistical analyses 
 
Statistical analyses were performed using Tukey’s method for multiple group comparisons 
using a statistical software program (JMP5.12-J, SAS Institute Inc., NC, USA). Differences 
with p < 0.05 were considered statistically significant. This study was inspected and approved 
by the Clinical Studies Ethical Review Committee of the University of Tsukuba, and the 
approval number was H27-240. 
  
 
3. Results 
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Using a different kit on an independent set of Japanese ALS patients and normal subjects, 
we initially attempted to replicate the results of Iłzecka et al. [13], who found no difference in 
the TGF-β1 concentration in the lumbar CSF between ALS patients and normal controls. In 
addition, we extended the analysis by testing the hypothesis that the CSF-TGF-β1 
concentrations in SCD and MSA-C patients may be increased compared to those in control 
subjects. 
Consistent with the previous report [13], the TGF-β1 levels in the CSF of ALS patients were 
not significantly higher than in the controls (Fig. 1, Table 2; p = 0.813). Furthermore, the CSF-
TGF-β1 concentration in the SCD and MSA-C patients did not differ markedly from control 
subjects (Fig. 1, Table 2; p = 1.000 and p = 0.970, respectively).  
 
 
4. Discussion 
 
Consistent with the results of Iłzecka et al. [13], we did not find any marked differences in 
the CSF-TGF-β1 level between ALS patients and normal subjects. To our knowledge, our study 
is the first to measure the TGF-β1 level in the CSF of patients with SCD and MSA-C. SCD and 
MSA-C are neurodegenerative diseases that have been hypothesized to show an inflammatory 
condition. Thus, the TGF-β1 level in the CSF of SCD and/or MSA-C patients was expected to 
be higher than in normal subjects. However, we failed to detect any significant differences in 
the CSF-TGF-β1 level between these patients and normal subjects. Our results suggest that the 
TGF-β1 level in the CSF is an unreliable diagnostic marker for SCD and MSA-C. 
The amount of TGF-β1 in the CSF is very small; therefore, careful performance of an ELISA 
assay is essential to obtain accurate data. As shown in Figure 1, the variation in the results for 
both the experimental and control groups was very small. Thus, our results are reliable. 
TGF-β1 acts as both a growth-inhibiting and growth-promoting factor, although the former 
aspect is often more potent than the latter [10]. Previous studies have reported an increase in 
the TGF-β1 levels in ALS model mice [14]; however, we did not detect any marked elevation 
in the TGF-β1 levels in the CSF of ALS patients. Iłzecka et al. [13] observed a significant but 
modest increase in the TGF-β1 levels in the CSF of 1 of 4 groups of ALS patients. Taken 
together with those from our study, these findings suggests that the TGF-β1 level in some 
patients with ALS, SCD, or MSA-C may be elevated due to some yet unknown influence; 
however, the use of TGF-β1 as a clinical biomarker is impractical. 
 
 
5. Conclusion 
 
No significant differences in the TGF-β1 levels in the CSF were observed between the 
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control subjects and patients with ALS, SCD and MSA-C. These results indicate that measuring 
the CSF-TGF-β1 level is not practical as a biomarker of ALS, SCD, or MSA-C. 
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Figure legend 
Fig. 1. An ELISA was used to measure the TGF-β1 concentration in the CSF for each 
diagnostic group. The mean values ± SD are shown using horizontal magenta lines for each 
group.  
Table 1  Diagnosis by gender and age.
Diagnosis Gender Age ± SD
Normal controls Male     (n = 8) 61.3 ± 12.1
Female  (n = 11)
ALS Male     (n = 17) 65.7 ± 11.3
Female  (n = 10)
SCD Male     (n = 9) 62.7 ± 10.3
Female  (n = 4)
MSA-C Male     (n = 9) 62.9 ± 5.1
Female  (n = 7)
SD; standard division
Table 2  Mean TGF-β1 levels in the CSF of ALS, SCD and MSA-C patients and normal controls.
TGF-β1 (pg/ml)
Diagnoses Mean ± SD Range P  value*
Normal controls (n = 27)   96.53 ± 24.12 51.51 - 156.65
ALS (n = 27) 103.75 ± 33.62 54.64 - 240.75 0.813
SCD (n = 17)   95.31 ± 22.82 61.74 - 139.52 1.000
MSA-C (n = 16)   92.39 ± 21.07 61.74 - 132.55 0.970
SD; standard division, *Tukey's test
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